Zacks Research upgraded shares of Elekta (OTCMKTS:EKTAY - Free Report) from a strong sell rating to a hold rating in a research report released on Tuesday morning,Zacks.com reports.
Several other research analysts have also commented on EKTAY. Danske lowered Elekta to a "hold" rating in a research report on Tuesday, June 3rd. UBS Group began coverage on Elekta in a research report on Wednesday, September 3rd. They issued a "sell" rating on the stock. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Reduce".
Read Our Latest Research Report on EKTAY
Elekta Trading Down 1.8%
Shares of EKTAY stock traded down $0.10 during mid-day trading on Tuesday, hitting $5.26. 2,758 shares of the company's stock were exchanged, compared to its average volume of 4,227. Elekta has a fifty-two week low of $4.36 and a fifty-two week high of $7.13. The stock has a 50-day simple moving average of $4.98 and a two-hundred day simple moving average of $5.09. The company has a quick ratio of 0.82, a current ratio of 1.05 and a debt-to-equity ratio of 0.63. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of 87.60 and a beta of 1.10.
Elekta (OTCMKTS:EKTAY - Get Free Report) last issued its earnings results on Thursday, August 28th. The company reported $0.03 earnings per share for the quarter. Elekta had a return on equity of 11.49% and a net margin of 1.40%.The firm had revenue of $379.64 million for the quarter. Equities analysts expect that Elekta will post 0.36 EPS for the current fiscal year.
Elekta Dividend Announcement
The company also recently disclosed a dividend, which will be paid on Friday, September 26th. Investors of record on Tuesday, September 9th will be issued a $0.0744 dividend. This represents a yield of 289.0%. The ex-dividend date of this dividend is Monday, September 8th. Elekta's payout ratio is currently 216.67%.
About Elekta
(
Get Free Report)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.
Read More
Before you consider Elekta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta wasn't on the list.
While Elekta currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.